Bimekizumab safe and effective for AS and PsA in long-term trials
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Bimekizumab is a humanized monoclonal antibody that targets IL-17A and IL-17F, potentially giving it greater therapeutic efficacy than inhibitors of only IL-17A. The long-term safety and
efficacy of bimekizumab have now been assessed in adults with ankylosing spondylitis (AS) or psoriatic arthritis (PsA) in two international, multicentre phase IIb randomized, controlled
trials (RCTs) and their open-label extensions.
In the BE AGILE study, 303 adults with active AS were enrolled in a 48-week RCT; 255 participated in the extension and 224 were still enrolled at study week 156. Overall, 280 participants
had one or more TEAE, including 43 with serious TEAE. Two deaths occurred, but neither was considered treatment-related. Treatment efficacy was demonstrated by ASAS40 response in 72.6% of
participants at week 156. Pain, fatigue and quality of life showed sustained improvement.
Anyone you share the following link with will be able to read this content: